These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12072310)

  • 1. Aspects of cyclosporine A toxicity in the development of coronary artery disease in transplant recipients.
    Hennersdorf F; Wellnhofer E; Musci M; Bocksch W; Spiegelsberger S; Heins S; Hetzer R; Fleck E
    Transplant Proc; 2002 Jun; 34(4):1185-8. PubMed ID: 12072310
    [No Abstract]   [Full Text] [Related]  

  • 2. C(2) monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses.
    Baraldo M; Francesconi A; Barbone F; Tursi V; Livi U; Furlanut M
    Transplant Proc; 2002 Dec; 34(8):3246-8. PubMed ID: 12493435
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
    Transplant Proc; 2006 Sep; 38(7):2032-4. PubMed ID: 16979990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cyclosporine in inducing hyperuricemia in heart transplant patients.
    Sahar G; Stamler A; Berman M; Ben Gal T; Vaturi M; Aravot D; Vidne BA
    Transplant Proc; 2000 Jun; 32(4):729-30. PubMed ID: 10856561
    [No Abstract]   [Full Text] [Related]  

  • 5. Implication of HLA mismatch in the clinical outcome of orthotopic heart transplantation.
    Aziz TM; Sheldon S; el-Gamel A; Krysiak P; Campbell C; Rahman A; Dyer P; Yonan N; Deiraniya A
    Transplant Proc; 1998 Aug; 30(5):1917-9. PubMed ID: 9723332
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
    Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
    Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
    [No Abstract]   [Full Text] [Related]  

  • 7. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study.
    Cantarovich M; Latter D; Fitchett D
    Transplant Proc; 1997; 29(1-2):602-4. PubMed ID: 9123149
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
    Heroux AL; LeBlanc MH; Beaudoin D; Simard S; Coulombe DA; Gleeton O; Lemieux MD; Doyle DP
    Transplant Proc; 1996 Dec; 28(6):3145-8. PubMed ID: 8962219
    [No Abstract]   [Full Text] [Related]  

  • 10. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral.
    Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K
    Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythrocyte-to-plasma distribution ratio of cyclosporine: a useful indicator to predict cyclosporine pharmacokinetics and physiological changes during cyclosporine monitoring.
    Shibata N; Hoshino N; Yamaji A; Park KI; Inoue H; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y
    Transplant Proc; 1996 Jun; 28(3):1313-5. PubMed ID: 8658674
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclosporine neoral monitoring and its correlation with the "area under the curve".
    Sabbatiello R; Sgrosso JL; Schiavelli R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3378. PubMed ID: 8962317
    [No Abstract]   [Full Text] [Related]  

  • 13. Risks and benefits of withdrawing cyclosporine from the long-term immunosuppression regimen of heart and heart-lung transplant recipients.
    Walker S; Habib S; Thompson D; Khaghani A; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1149-51. PubMed ID: 9636465
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients.
    Preuner JG; Lehle K; Keyser A; Merk J; Rupprecht L; Goebels R
    Transplant Proc; 1998 Dec; 30(8):3943-4. PubMed ID: 9865253
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.
    Gaspari F; Anedda MF; Signorini O; Amuchastegui SC; Perico N; Remuzzi G
    Transplant Proc; 1998 Aug; 30(5):1654-5. PubMed ID: 9723229
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of cyclosporine MEPC (Neoral) in heart transplant recipients.
    Fukushima N; Ohtake S; Sawa Y; Nishimura M; Kobayashi Y; Shirakura R; Nakata S; Matsuda H
    Transplant Proc; 1998 Nov; 30(7):3337-8. PubMed ID: 9838473
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose- and time-related acceleration of chronic graft vascular disease caused by cyclosporine in a rat cardiac isograft model.
    Teranishi K; Usui A; Maseki T; Watanabe T; Yasuura K; Imaizumi M
    Transplant Proc; 1999 Nov; 31(7):2801-3. PubMed ID: 10578298
    [No Abstract]   [Full Text] [Related]  

  • 18. C(2) blood levels in heart-transplanted patients immunosuppressed on a trough level-based regimen.
    Fiocchi R; Iamele L; Torre L; Papageorgiou C; Gamba A; Ferrazzi P
    Transplant Proc; 2001; 33(7-8):3115-6. PubMed ID: 11750339
    [No Abstract]   [Full Text] [Related]  

  • 19. Study of circadian variation of cyclosporine pharmacokinetics.
    Milanian I; Ghods AJ; Mahmoudian M; Proushani-Nia F; Nejad Gashti H; Abdi E; Abbasi M
    Transplant Proc; 1997 Nov; 29(7):2930-1. PubMed ID: 9365618
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine A is associated with a shift of the Th1/Th2 balance in liver transplant patients.
    van den Berg AP; Twilhaar WN; Corver K; Geerts AB; Mesander G; Klompmaker IJ; Slooff MJ; The TH; de Leij LH
    Transplant Proc; 1998 Aug; 30(5):2378-9. PubMed ID: 9723510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.